



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

engineered to target HBsAg.⁹ All these novel agents have remained in early-phase drug development and preliminary results have not indicated that any of them can cure HBV infection alone. Reliance on antivirals without immunomodulation is also insufficient to cure the infection because the production of HBsAg can be maintained by integrated HBV DNA,¹⁰ which antiviral agents do not act on directly. Therefore, most patients will require combination therapy comprising several classes of therapeutic agents with different mechanisms of action to sustainably clear their blood of HBsAg. There is a great amount of work required and daunting challenges to overcome to achieve the goal of curing chronic HBV infection. A greater commitment from public and private sectors is needed to reach this end.

Y-CH has received research support from Gilead Sciences; has served as an advisory board member or consultant for Gilead Sciences; and has served as a speaker for AbbVie, Bristol Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, and Novartis. In the past 36 months, MHN has received research support from Pfizer, Enanta, AstraZeneca, Innogen, Exact Science, CurveBio, Gilead Sciences, Exact Sciences, Vir Biotech, Helio Health, the National Cancer Institute, Glycotest, and the B.K. Kee Foundation and has served as an advisory board member or consultant for Intercept, Exact Science, Gilead Sciences, GSK, Eli Lilly, the Laboratory for Advanced Medicine, and Exelixis. We received no external funding for this Comment but Y-CH wishes to acknowledge research grant support from the National Science and Technology Council in Taiwan (110-2314-B-214-006-MY3).

Yao-Chun Hsu, *Mindie H Nguyen
mindiehn@stanford.edu

Center for Liver Diseases, E-Da Hospital, Kaohsiung, Taiwan (Y-CH); School of Medicine, I-Shou University, Kaohsiung, Taiwan (Y-CH); Division of Gastroenterology, Fu-Jen Catholic University Hospital, New Taipei, Taiwan (Y-CH); Institute of Biomedical Informatics, National Yang Ming Chiao Tung University, New Taipei, Taiwan (Y-CH); Department of Medicine (MHN) and Department of Epidemiology and Population Health (MHN), Stanford University Medical Center, Palo Alto, CA 94304, USA

- 1 Yuen M-F, Balabanska R, Cottreel E, et al. TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial. *Lancet Infect Dis* 2022; published online Dec 9. [https://doi.org/10.1016/S1473-3099\(22\)00727-7](https://doi.org/10.1016/S1473-3099(22)00727-7).
- 2 Tan M, Bhadoria AS, Cui F, et al. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2021; **6**: 106–19.
- 3 Lok AS, McMahon BJ, Brown RS Jr, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. *Hepatology* 2016; **63**: 284–306.
- 4 Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology* 2018; **67**: 1560–99.
- 5 Yip TC, Wong GL, Chan HL, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. *J Hepatol* 2019; **70**: 361–70.
- 6 Ye Q, Kam LY, Yeo YH, et al. Substantial gaps in evaluation and treatment of patients with hepatitis B in the US. *J Hepatol* 2022; **76**: 63–74.
- 7 Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. *Gut* 2012; **61**: 1754–64.
- 8 Nguyen MH, Lim JK, Burak Ozbay A, et al. Advancing age and comorbidity in a US insured population-based cohort of patients with chronic hepatitis B. *Hepatology* 2019; **69**: 959–73.
- 9 Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development? *J Hepatol* 2022; **76**: 1249–62.
- 10 Grudda T, Hwang HS, Taddese M, et al. Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment. *J Clin Invest* 2022; **132**: e161818.

Why we need a deeper understanding of the pathophysiology of long COVID



The most recent estimate of people living with post-COVID-19 condition (also known as long COVID) globally has surpassed 65 million¹ and, without clear diagnostic or treatment options available, this number is steadily increasing. There are more than 200 reported symptoms associated with long COVID,¹ affecting virtually every organ system.

Although some long haulers recover, many people have had symptoms since early 2020. The condition is a blanket diagnosis that represents a heterogeneous set of pathophysiological processes. As such, several factors can affect the presentation of long COVID, such as the severity of acute infection, age, sex, pre-existing comorbidities, genetics, socioeconomic factors, and other environmental factors. Long haulers

who survived severe acute SARS-CoV-2 infection are most likely to be men older than 50 years with lingering tissue damage and scarring. People with long COVID after a less-severe infection are most likely to be younger women (aged 36–50 years) whose acute infection has triggered adverse physiological responses.

The main disease hypotheses for the root causes of long COVID include viral persistence (infectious virus, viral RNA, or viral proteins), autoimmunity triggered by the infection, reactivation of latent viruses, and inflammation-triggered chronic changes leading to tissue dysfunction and damage (figure).

There is growing and compelling evidence that SARS-CoV-2 infects and produces its RNA and proteins

Published Online
February 14, 2023
[https://doi.org/10.1016/S1473-3099\(23\)00053-1](https://doi.org/10.1016/S1473-3099(23)00053-1)




Figure: Causal model of interaction of viral persistence, autoimmunity, latent viral reactivation, and tissue damage and dysfunction as root cause drivers of Long COVID

in a wide range of cell types in tissues, including the gastrointestinal, respiratory, cardiovascular, lymphoid, endocrine, urogenital, ocular, skin, muscular, and peripheral nervous system and CNS tissues.² Circulating spike proteins are observed in 60% of patients with long COVID between 2 and 12 months after infection.³ Although the presence of viral RNA and proteins do not necessarily indicate persistent infection, viral RNA can trigger innate immune responses and viral proteins might cause tissue damage and stimulate persistent activation of lymphocytes, which lead to chronic inflammation.

In people with long COVID, assessment of autoantibodies to human exoproteome using rapid extracellular antigen profiling revealed no significant

differences from people without long COVID.⁴ However, autoantibodies to intracellular antigens⁵ or autoreactive T cells might have a role in long COVID.

There is also emerging evidence for latent herpesviruses reactivation in people with long COVID. Reactivation of latent Epstein-Barr virus, but not the acute mononucleosis infection, is found in people with long COVID,^{4,6} and Epstein-Barr virus viraemia at the time of acute COVID is predictive for long COVID.⁵

Local inflammatory response to SARS-CoV-2 in one organ can cause lasting alterations in distant tissues and organs. In a mouse model, even mild lung-restricted COVID-19 (in which the infectious virus became undetectable within a week) was found to induce prolonged changes in the CNS, including

microglial activation, oligodendrocyte loss, and reduced myelination, for up to 7 weeks after infection.⁷

Beyond these potential root causes, many secondary pathological changes have been observed in people with long COVID, including the formation of microclots and platelet activation,⁸ reduced cortisol,^{4,5} and mitochondrial dysfunction.⁹

Despite the multifactorial pathogenesis, available data show that long COVID is an organic post-acute infection syndrome (PAIS) with clear physiological dysfunction that is often not consistently apparent using standard medical diagnostic tests. This discrepancy highlights the need for a new generation of more sensitive testing procedures for people with PAIS. Although it is not known whether pre-existing psychological diagnoses might influence the risk of long COVID (eg, by affecting the host endocrine and immune systems), it is neither productive nor clinically or scientifically valid to classify long COVID as a psychosomatic condition.

As avoiding COVID-19 becomes increasingly difficult, we argue that deep biological analyses will identify biomarkers for long COVID and possibly identify distinct endotypes driven by different root causes so that the risk of contracting long COVID is better defined. Biomarker identification will not only be crucial for identifying predisposing factors but also allow us to implement safer, evidence-based policies. Similarly, molecular, cellular, and physiological analyses will inform precision interventions that target the root causes of each long COVID endotype. For example, persistent viral infection could be targeted by antivirals; long COVID driven by autoimmune disease could be treated using monoclonal antibodies that target lymphocytes or drugs that block cytokines and cytokine signalling; and, if the reactivation of herpesviruses contributes to disease, targeting such viruses using antivirals or vaccines could be considered. Diagnostic criteria considering the root causes to prevent and treat long COVID will require large longitudinal studies. If therapeutic targeting of root causes is not feasible, the downstream pathological changes of long COVID could still be treated.

Ideally, potential therapies should be assessed in double-blinded, placebo-controlled, randomised clinical

trials. However, such studies are quite costly, are labour intensive, and require substantial government, regulatory, and industry support.

Syndromes like Long COVID are not new. Other PAISs, such as myalgic encephalomyelitis and chronic fatigue syndrome and post-treatment Lyme disease syndrome, have overlapping symptoms with long COVID.¹⁰ Thus, the inclusion of individuals with other forms of PAIS as comparison groups in long COVID research is important for broadening overall understanding and widening the impact of this research. Finally, the current knowledge surrounding long COVID would not be possible without the hard work and dedication of patient-led communities striving for answers.

AI is a principal investigator in a decentralised phase 2 efficacy and safety study of nirmatrelvir and ritonavir in adult participants with long COVID (PAXLC; NCT05668091); is a consultant for RIGImmune, Xanadu Bio, Invisishield, and Paratus Bio; and is the vice president of the American Association of Immunologists. DP declares no competing interest.

Akiko Iwasaki, David Putrino
akiko.iwasaki@yale.edu

Center for Infection and Immunity, and Department of Immunobiology, Yale School of Medicine, New Haven, CT 06520, USA (AI); Howard Hughes Medical Institute, Chevy Chase, MD, USA (AI); Abilities Research Center, Icahn School of Medicine at Mount Sinai, New York City, NY, USA (DP); Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York City, NY, USA (DP)

- 1 Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. *Nat Rev Microbiol* 2023; published online Jan 13. <https://doi.org/10.1038/s41579-022-00846-2>.
- 2 Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. *Nature* 2022; **612**: 758–63.
- 3 Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. *Clin Infect Dis* 2022; published online Sept 2. <https://doi.org/10.1093/cid/ciac722>.
- 4 Klein J, Wood J, Jaycox J, et al. Distinguishing features of long COVID identified through immune profiling. *medRxiv* 2022; published online Aug 10. <https://doi.org/10.1101/2022.08.09.22278592> (preprint).
- 5 Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. *Cell* 2022; **185**: 881–95.
- 6 Peluso MJ, Deveau TM, Munter SE, et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. *J Clin Invest* 2023; published online Feb 1. <https://doi.org/10.1172%2FJCI163669>.
- 7 Fernández-Castañeda A, Lu P, Geraghty AC, et al. Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. *Cell* 2022; **185**: 2452–68.e16.
- 8 Pretorius E, Venter C, Laubscher GJ, et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with long COVID/post-acute sequelae of COVID-19 (PASC). *Cardiovasc Diabetol* 2022; **21**: 148.
- 9 Guntur VP, Nemkov T, de Boer E, et al. Signatures of mitochondrial dysfunction and impaired fatty acid metabolism in plasma of patients with post-acute sequelae of COVID-19 (PASC). *Metabolites* 2022; **12**: 1026.
- 10 Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. *Nat Med* 2022; **28**: 911–23.